Core Viewpoint - The stock of Jinyu Biological Technology Co., Ltd. has shown significant price movements, with a year-to-date increase of 58.86% and a recent trading volume indicating active market participation [1][2]. Company Overview - Jinyu Biological Technology Co., Ltd. is located in Hohhot, Inner Mongolia, and was established on March 13, 1993, with its stock listed on January 15, 1999. The company primarily engages in the research, production, and sales of veterinary biological products [1]. - The main revenue composition includes 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1]. Financial Performance - For the period from January to September 2025, the company achieved an operating income of 1.042 billion yuan, representing a year-on-year growth of 7.38%. However, the net profit attributable to shareholders decreased by 4.85% to 161 million yuan [2]. - Cumulatively, the company has distributed 2.219 billion yuan in dividends since its A-share listing, with 189 million yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 10.70% to 49,000, while the average number of tradable shares per person increased by 11.12% to 22,673 shares [2]. - Notable institutional holdings include the Guotai Zhongzheng Livestock Breeding ETF, which is the fourth-largest shareholder with 25.0398 million shares, an increase of 9.0897 million shares from the previous period [3].

Core Viewpoint - Mingde Biological's stock has shown a mixed performance in recent trading sessions, with a year-to-date increase of 14.50% and a notable decline of 8.77% over the past 60 days [1] Financial Performance - For the period from January to September 2025, Mingde Biological reported revenue of 227 million yuan, reflecting a year-on-year growth of 0.53%. However, the net profit attributable to shareholders decreased significantly by 83.30% to 13.52 million yuan [2] - Cumulatively, since its A-share listing, Mingde Biological has distributed a total of 1.76 billion yuan in dividends, with 875 million yuan distributed over the past three years [3] Shareholder Structure - As of October 31, 2025, the number of shareholders for Mingde Biological decreased by 2.27% to 23,100, while the average number of circulating shares per person increased by 2.32% to 6,763 shares [2] - The top ten circulating shareholders include notable funds such as GF Value Core Mixed A and Rongtong China Wind 1, with some new entrants and changes in holdings among the top shareholders [3] Market Activity - On November 12, Mingde Biological's stock price rose by 2.01% to 19.77 yuan per share, with a trading volume of 39.1 million yuan and a turnover rate of 1.28% [1] - The stock experienced a net outflow of 204,300 yuan from major funds, while large orders showed mixed buying and selling activity [1] Business Overview - Mingde Biological, established on January 28, 2008, specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, with a revenue composition of 65.04% from in vitro diagnostic products, 21.91% from third-party medical testing, and 13.05% from agency and other businesses [1] - The company operates within the pharmaceutical and biological industry, specifically in the medical device and in vitro diagnostic sectors [1]

Core Viewpoint - Oriental Bio's stock price has shown fluctuations, with a recent increase of 2.10% to 27.75 CNY per share, while the company has experienced a year-to-date decline of 5.39% [1] Financial Performance - For the period from January to September 2025, Oriental Bio reported a revenue of 672 million CNY, reflecting a year-on-year growth of 2.16% [2] - The company recorded a net profit attributable to shareholders of -213 million CNY, which is an improvement of 18.89% compared to the previous period [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Oriental Bio was 13,300, a decrease of 3.93% from the previous period [2] - The average number of circulating shares per shareholder increased by 4.09% to 15,170 shares [2] Dividend Distribution - Since its A-share listing, Oriental Bio has distributed a total of 1.607 billion CNY in dividends, with 336 million CNY distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the fourth largest circulating shareholder is Rongtong Health Industry Flexible Allocation Mixed A/B, holding 2.8 million shares, a decrease of 1.7001 million shares from the previous period [3] - Hong Kong Central Clearing Limited is the sixth largest shareholder, with 1.4675 million shares, an increase of 139,400 shares [3] - The Southern Science and Technology Innovation Board 3-Year Open Mixed Fund holds 780,900 shares, unchanged from the previous period [3]

Core Viewpoint - TaiLong Pharmaceutical has shown a significant stock price increase of 36.94% year-to-date, with recent trading activity indicating positive market sentiment and liquidity [1][2]. Financial Performance - For the period from January to September 2025, TaiLong Pharmaceutical reported a revenue of 1.187 billion yuan, representing a year-on-year decrease of 11.47%. The net profit attributable to shareholders was 25.33 million yuan, down 12.36% compared to the previous year [2]. - The company has cumulatively distributed 112 million yuan in dividends since its A-share listing, with 15.53 million yuan distributed over the last three years [3]. Stock Market Activity - As of November 11, TaiLong Pharmaceutical's stock price was 6.97 yuan per share, with a market capitalization of 4 billion yuan. The stock experienced a trading volume of 50.41 million yuan and a turnover rate of 1.28% [1]. - The stock has seen a net inflow of 2.36 million yuan from main funds, with large orders accounting for 22.95% of total purchases [1]. Shareholder Information - As of September 30, 2025, the number of shareholders for TaiLong Pharmaceutical was 40,400, a decrease of 1.08% from the previous period. The average number of tradable shares per shareholder increased by 1.09% to 14,190 shares [2]. - Among the top ten circulating shareholders, Guangfa Pension Index A held 2.9719 million shares, a decrease of 264,000 shares from the previous period, while Huatai-PineBridge CSI Traditional Chinese Medicine ETF entered as a new shareholder with 2.8616 million shares [3].

Core Viewpoint - Zhongmu Co., Ltd. has shown a positive stock performance with an 18.29% increase year-to-date and a significant rise in net profit for the first nine months of 2025, indicating strong operational growth in the animal health sector [1][2]. Financial Performance - As of September 30, 2025, Zhongmu Co., Ltd. achieved a revenue of 4.442 billion yuan, representing a year-on-year growth of 6.32% [2]. - The net profit attributable to shareholders reached 225 million yuan, marking a substantial increase of 175.49% compared to the previous year [2]. Stock Market Activity - On November 10, 2025, Zhongmu's stock price rose by 2.06% to 7.91 yuan per share, with a trading volume of 71.25 million yuan and a turnover rate of 0.89% [1]. - The company has a total market capitalization of 8.077 billion yuan [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 6.45% to 36,900, while the average number of circulating shares per person increased by 6.90% to 27,706 shares [2][3]. - The top ten circulating shareholders include significant institutional investors, with notable changes in holdings among major ETFs [3]. Business Overview - Zhongmu Co., Ltd. specializes in animal health products, including vaccines, diagnostic liquids, and veterinary drugs, with a revenue composition of 35.78% from chemical drugs, 27.87% from trade, 19.21% from feed, and 16.10% from biological products [1]. - The company is categorized under the agricultural and animal health sectors, with involvement in various concepts such as small-cap stocks and rural revitalization [1].

Core Viewpoint - Zhejiang Medicine's stock price increased by 2.05% on November 7, reaching 14.93 CNY per share, with a total market capitalization of 14.357 billion CNY [1] Financial Performance - For the period from January to September 2025, Zhejiang Medicine reported operating revenue of 6.695 billion CNY, a year-on-year decrease of 5.87%, while net profit attributable to shareholders increased by 9.83% to 933 million CNY [2] - Cumulative cash dividends since the company's A-share listing amount to 4.377 billion CNY, with 661 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 3.83% to 63,000, while the average circulating shares per person increased by 3.98% to 15,258 shares [2] - The third-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 46.6455 million shares, a decrease of 24.6449 million shares from the previous period [3]

Core Viewpoint - Kangyuan Pharmaceutical's stock has shown fluctuations with a year-to-date increase of 11.38%, but recent performance indicates a decline over the past 60 days by 10.82% [1] Group 1: Stock Performance - As of November 7, Kangyuan Pharmaceutical's stock price reached 15.17 CNY per share, with a trading volume of 73.44 million CNY and a turnover rate of 0.86% [1] - The stock has experienced a net outflow of 429,200 CNY from main funds, with large orders showing a buy of 11.98 million CNY and a sell of 12.21 million CNY [1] - Over the last five trading days, the stock has increased by 1.47%, while it has decreased by 1.56% over the last 20 days [1] Group 2: Financial Performance - For the period from January to September 2025, Kangyuan Pharmaceutical reported a revenue of 2.343 billion CNY, representing a year-on-year decrease of 24.66% [2] - The net profit attributable to shareholders for the same period was 200 million CNY, down 44.10% compared to the previous year [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Kangyuan Pharmaceutical increased to 40,500, marking a rise of 17.20% [2] - The average number of circulating shares per person decreased by 14.68% to 13,969 shares [2] - The company has distributed a total of 949.8 million CNY in dividends since its A-share listing, with 345 million CNY distributed over the last three years [3]

Core Viewpoint - TianKang Biological has shown a mixed performance in stock price and financial results, with a notable increase in stock price year-to-date but a decline in net profit for the recent period [1][2]. Group 1: Stock Performance - On November 7, TianKang Biological's stock rose by 2.03%, reaching 7.53 CNY per share, with a trading volume of 80.02 million CNY and a turnover rate of 0.79% [1]. - The stock has increased by 18.96% year-to-date, with a 2.03% rise in the last five trading days, a 2.46% decline over the last 20 days, and a 16.74% increase over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, TianKang Biological reported a revenue of 13.61 billion CNY, representing a year-on-year growth of 4.00%, while the net profit attributable to shareholders decreased by 27.20% to 412 million CNY [2]. - The company has distributed a total of 1.89 billion CNY in dividends since its A-share listing, with 598 million CNY distributed in the last three years [3]. Group 3: Business Overview - TianKang Biological, established on December 28, 2000, and listed on December 26, 2006, is based in Urumqi, Xinjiang, and specializes in the production and sales of biological vaccines for livestock, feed, and plant protein [1]. - The revenue composition of the company includes 32.20% from the pig breeding industry chain, 27.51% from feed, 16.37% from protein and oil processing, 14.75% from corn, 5.44% from veterinary drugs, and 3.40% from other sources [1]. Group 4: Shareholder Information - As of October 31, the number of shareholders for TianKang Biological was 58,000, a decrease of 3.11% from the previous period, with an average of 23,548 circulating shares per shareholder, an increase of 3.21% [2]. - Notable institutional holdings include Guotai Zhongzheng Livestock Breeding ETF as the fifth-largest shareholder with 24.30 million shares, and Hong Kong Central Clearing Limited as the seventh-largest shareholder with 15.03 million shares, marking a new entry [3].

Core Viewpoint - Tianbang Food's stock has experienced a decline in recent trading sessions, with a notable drop in both revenue and net profit year-on-year, indicating potential challenges in the company's financial performance [1][2]. Group 1: Stock Performance - On November 7, Tianbang Food's stock fell by 2.07%, trading at 2.84 CNY per share, with a total market capitalization of 6.31 billion CNY [1]. - The stock has increased by 1.79% year-to-date, but has seen declines of 1.39% over the last five trading days, 2.07% over the last twenty days, and 7.19% over the last sixty days [1]. - The company has appeared on the trading leaderboard once this year, with a net buy of 20.53 million CNY on May 8 [1]. Group 2: Financial Performance - For the period from January to September 2025, Tianbang Food reported a revenue of 6.72 billion CNY, a year-on-year decrease of 5.98%, and a net profit attributable to shareholders of 260 million CNY, down 80.65% year-on-year [2]. - The company has distributed a total of 1.185 billion CNY in dividends since its A-share listing, with no dividends paid in the last three years [2]. Group 3: Business Overview - Tianbang Food, established on September 25, 1996, and listed on April 3, 2007, is primarily engaged in pig farming and pork product processing, with revenue contributions of 63.82% from pig farming, 33.25% from food processing, 2.85% from feed products, and 0.08% from other sources [1]. - The company operates within the agricultural sector, specifically in the pig farming industry, and is associated with various concepts including the metaverse, pork, prepared dishes, animal vaccines, and avian influenza medications [2].

Core Viewpoint - Yiling Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.01% and a year-to-date increase of 11.71% [1] Financial Performance - For the period from January to September 2025, Yiling Pharmaceutical reported revenue of 5.868 billion yuan, a year-on-year decrease of 7.82%, while net profit attributable to shareholders was 1 billion yuan, reflecting a year-on-year increase of 80.33% [2] Stock Market Activity - As of November 4, 2025, Yiling Pharmaceutical's stock price was 17.55 yuan per share, with a market capitalization of 29.321 billion yuan. The stock has seen a trading volume of 253 million yuan and a turnover rate of 1.04% [1] - The stock has appeared on the "Dragon and Tiger List" once this year, with a net purchase of 64.05 million yuan on January 6 [1] Shareholder Information - As of September 30, 2025, the number of shareholders was 152,700, a decrease of 10.22% from the previous period, with an average of 9,013 circulating shares per person, an increase of 11.38% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 8.1119 million shares, and a new shareholder, Changxin Jinli Trend Mixed A, holding 5.95 million shares [3] Dividend Distribution - Yiling Pharmaceutical has distributed a total of 4.455 billion yuan in dividends since its A-share listing, with 1.838 billion yuan distributed in the last three years [3] Industry Classification - Yiling Pharmaceutical is classified under the pharmaceutical and biological sector, specifically in traditional Chinese medicine [2]